Table 4.
Best overall response to treatment
| Response, n (%) | ENC + CTX n = 26 | ENC + ALP + CTX n = 28 |
|---|---|---|
| Complete response (CR) | 1 (3.8) | 0 |
| Partial response (PR) | 4 (15.4) | 5 (17.9) |
| Stable disease* (SD) | 15 (57.7) | 21 (75.0) |
| Progressive disease (PD) | 4 (15.4) | 1 (3.6) |
| Unknown | 2 (7.7) | 1 (3.6) |
| Overall response rate (CR + PR) | 5 (19.2) | 5 (17.9) |
| Disease control rate (CR + PR + SD) | 20 (76.9) | 26 (92.8) |
Abbreviations: ENC + ALP + CTX, encorafenib combined with alpelisib and cetuximab; ENC + CTX, encorafenib combined with cetuximab.
*
In the ENC + CTX group, 1 patient with SD had unconfirmed PR, and 4 patients in the ENC + ALP + CTX group with SD had unconfirmed PR.